Stephen Mitchener - May 30, 2021 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role: SVP, Chief Business Officer
Signature: /s/ Nancy Smith as Attorney-in-Fact for Stephen Mitchener
Stock symbol: KPTI
Transactions as of: May 30, 2021
Transactions value $: $0
Form type: 4
Date filed: 6/1/2021, 04:05 PM
Next filing: Jun 3, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KPTI	Common Stock	Options Exercise		+1.5K	+100%		3K	May 30, 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KPTI	Restricted Stock Units	Options Exercise	$0	-1.5K	-50%	$0.00	1.5K	May 30, 2021	Common Stock	1.5K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units ("RSUs") convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.
F2	The reporting person has reported a prior award of 3,000 RSUs (described in footnote 3 below) in Table II of Form 4. The total reported in Column 5 includes 1,500 RSUs previously reported in Table II and 1,500 shares of common stock.
F3	On November 30, 2020, the reporting person was granted 3,000 RSUs, which vested as to 50% of the shares on May 30, 2021, with the remaining 50% vesting on November 30, 2021. 1,500 of the RSUs vested on May 30, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.